In the past week, CVKD stock has gone down by -5.37%, with a monthly gain of 19.00% and a quarterly surge of 124.69%. The volatility ratio for the week is 13.94%, and the volatility levels for the last 30 days are 11.80% for Cadrenal Therapeutics Inc The simple moving average for the past 20 days is -4.56% for CVKD’s stock, with a 47.06% simple moving average for the past 200 days.
Is It Worth Investing in Cadrenal Therapeutics Inc (NASDAQ: CVKD) Right Now?
Additionally, the 36-month beta value for CVKD is 1.55. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CVKD is 0.44M and currently, short sellers hold a 5.43% ratio of that float. The average trading volume of CVKD on November 05, 2024 was 50.01K shares.
CVKD) stock’s latest price update
Cadrenal Therapeutics Inc (NASDAQ: CVKD) has seen a decline in its stock price by -18.86 in relation to its previous close of 17.60. However, the company has experienced a -5.37% decline in its stock price over the last five trading sessions. prnewswire.com reported 2024-11-01 that PONTE VEDRA, Fla., Nov. 1, 2024 /PRNewswire/ — Cadrenal Therapeutics, Inc., (“Cadrenal” or the “Company”) (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 285,715 shares of common stock of the originally issued in July 2023, having an exercise price of $26.25 per share, at a reduced exercise price of $16.50 per share.
Analysts’ Opinion of CVKD
Many brokerage firms have already submitted their reports for CVKD stocks, with Noble Capital Markets repeating the rating for CVKD by listing it as a “Outperform.” The predicted price for CVKD in the upcoming period, according to Noble Capital Markets is $4 based on the research report published on December 18, 2023 of the previous year 2023.
CVKD Trading at 17.14% from the 50-Day Moving Average
After a stumble in the market that brought CVKD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.13% of loss for the given period.
Volatility was left at 11.80%, however, over the last 30 days, the volatility rate increased by 13.94%, as shares surge +19.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +94.02% upper at present.
During the last 5 trading sessions, CVKD fell by -5.37%, which changed the moving average for the period of 200-days by -7.57% in comparison to the 20-day moving average, which settled at $14.96. In addition, Cadrenal Therapeutics Inc saw 28.67% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CVKD
Current profitability levels for the company are sitting at:
- -2394.75 for the present operating margin
- 0.18 for the gross margin
The net margin for Cadrenal Therapeutics Inc stands at -2253.17. The total capital return value is set at -1.66. Equity return is now at value -174.01, with -138.35 for asset returns.
Based on Cadrenal Therapeutics Inc (CVKD), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -532.95. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 488.59.
Currently, EBITDA for the company is -7.63 million with net debt to EBITDA at 0.77. When we switch over and look at the enterprise to sales, we see a ratio of 3689.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.60.
Conclusion
In conclusion, Cadrenal Therapeutics Inc (CVKD) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
